References:

1. Catella-Lawson F, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-17

2. Kurth K, et al. Inhibition of clinical benefits on first myocardial infarction by nonsteroids anti-inflammatory drugts. Circulation 2003;108:1191-5.

3. Kimmel SE, Strom BL. Giving aspirin and ibuprofen after myocardial infarction. Clinical consequences are still unknown. Br Med J. 2003;327:1298-99.

4. MacDoanld TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-4.

5. Curtis JP, et al. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. Br Med J 2003;327:1322-23

6. Wilner KD, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027-30.

7. Greenberg HE, et al. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000;40:1509-15.